A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show.

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some ...

Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

Adoptive cell transfer with chimeric antigen receptor (CAR)-expressing T cells can induce remarkable complete responses in ...